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Background: Disruptive behavior is common in Alz-
heimer disease (AD). There are conflicting reports re-
garding its ability to predict cognitive decline, func-
tional decline, institutionalization, and mortality.
Objective: To examine whether the presence of dis-
ruptive behavior has predictive value for important out-
comes in AD.
Design: Using the Columbia University Scale for Psy-
chopathology in Alzheimer Disease (administered
every 6 months, for a total of 3438 visit-assessments
and an average of 6.9 per patient), the presence of
disruptive behavior (wandering, verbal outbursts,
physical threats/violence, agitation/restlessness, and
sundowning) was extracted and examined as a time-
dependent predictor in Cox models. The models con-
trolled for the recruitment cohort, recruitment center,
informant status, sex, age, education, a comorbidity
index, baseline cognitive and functional performance,
and neuroleptic use.
Setting: Five university-based AD centers in the United
States and Europe (Predictors Study).
Participants: Four hundred ninety-seven patients with
early-stage AD (mean Folstein Mini-Mental State Exami-
nation score, 20 of 30 at entry) who were recruited and
who underwent semiannual follow-up for as long as 14
(mean, 4.4) years.
MainOutcomeMeasures: Cognitive (Columbia Mini-
Mental State Examination score, 20 of 57 [approxi-
mate Folstein Mini-Mental State Examination score,10
of 30]) and functional (Blessed Dementia Rating Scale
score, parts I and II, 10) ratings, institutionalization
equivalent index, and death.
Results: At least 1 disruptive behavioral symptom was
noted in 48% of patients at baseline and in 83% at any evalu-
ation. Their presence was associated with increased risks
of cognitive decline (hazard ratio 1.45 [95% confidence in-
terval (CI), 1.03-2.03]), functional decline (1.66 [95% CI,
1.17-2.36]), and institutionalization (1.47 [95% CI, 1.10-
1.97]). Sundowning was associated with faster cognitive
decline, wandering with faster functional decline and in-
stitutionalization, and agitation/restlessness with faster cog-
nitive and functional decline. There was no association be-
tween disruptive behavior and mortality (hazard ratio, 0.94
[95% CI, 0.71-1.25]).
Conclusion: Disruptive behavior is very common in AD
and predicts cognitive decline, functional decline, and
institutionalization but not mortality.
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D ISRUPTIVE BEHAVIORALsymptoms (DBSs) such asagitation, verbal andphysical aggression, andwandering are well-
recognized symptoms in Alzheimer dis-
ease (AD), with reported frequencies rang-
ing from 6% to 57%,1-7 depending on
symptom definition and the stage of ill-
ness examined. For example, in a popu-
lation-based study, 40% of demented pa-
tients manifested symptoms of agitation/
aggression; 18%, disinhibition; and 34%,
irritability.4 The presence of such fea-
tures in AD is not only a source of care-
giver distress8-10 and financial burden (be-
cause of the need for medication treatment,
hospitalizations, and nursing home place-
ment) but also potentially associated with
important disease outcomes.
Reports examining the association
between DBSs and various disease out-
comes have been conflicting. Some stud-
ies have reported an association between
agitation/aggression and faster cognitive de-
cline1,10-15; between wandering/purpose-
less, inappropriate activities, or aggressive
behavior and functional decline2,10,15; be-
tween agitation/aggression and increased
risk of institutionalization16-19; and be-
tween agitation/wandering and increased
mortality risk.20,21 However, other reports
failed to detect significant associations
between disruptive behavior and cog-
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nition,2 , 1 6 function,1 5 institutionalization,2 or
mortality.2,21
Many factors contribute to the variability in reported
associations, including variability in the definitions of
DBSs, inconsistent consideration of treatment with neu-
roleptics, use of standardized scales vs clinical evalua-
tion, inclusion of subjects at varying stages of disease,
and variable levels of participation at and duration of fol-
low-up. Also, most previous studies considered DBSs only
at a single point during the course of AD, typically at the
baseline visit or, less frequently, at any point during the
disease course. Because of the progressive nature of AD
and the fact that neuroleptic medications can be effec-
tive in managing these symptoms, these features are not
static and invariable but may fluctuate from visit to
visit.5,7,22 Therefore, consideration of DBSs as fixed-time
variables may lead to bias toward the null.
To investigate these issues, we analyzed data from a
large, multicenter cohort of patients with probable AD
who were followed up from the early stages of the dis-
ease for up to 14 years, using semiannual standardized
assessments of DBSs in a time-dependent fashion as pre-
dictors of important disease outcomes.
METHODS
PARTICIPANTS
Subjects from the Predictors Study 1 and 2 cohorts23-25 were in-
cluded in these analyses. For the Predictors Study 1 cohort, pa-
tients were recruited and studied at the following 3 sites in the
United States: Columbia University, The Johns Hopkins Univer-
sity, and Harvard University. For the Predictors Study 2 cohort,
the following 2 sites in the European Union were added to the 3
US sites (leading to 5 recruitment sites overall): Hospital de la
Salpeˆtrière and the University of Thessaly. The study was ap-
proved by the appropriate local institutional review boards.
Participants were recruited from a population of subjects who
were seen at outpatient clinics of these institutions that special-
ized in memory disorders, aging, and dementia. Subjects under-
going evaluation in these clinics were referred from other medi-
cal specialties or other neurological subspecialties or were self-
referred. The inclusion and exclusion criteria and the evaluation
procedures of the Predictors Study have been fully described else-
where.23-26 Briefly, patients met Diagnostic and Statistical Manual
of Mental Disorders (Third Edition Revised) criteria for primary
degenerative dementia of the Alzheimer type and National Insti-
tute of Neurological and Communicative Disorders and Stroke–
Alzheimer’s Disease and Related Disorder Association criteria for
probable AD. Enrollment required a Columbia Mini-Mental State
Examination (MMSE) score of at least 30 of 57 (approximately
16 of 30 on the Folstein MMSE27,28). The present analyses in-
clude 40 additional subjects who were recruited in the study de-
spite a Columbia MMSE of less than 30 (removal of whom did
not change the results). Exclusion criteria were parkinsonism,




A physician or a trained research technician administered the
Columbia University Scale for Psychopathology in Alzheimer
Disease (CUSPAD)6 to the informant at the initial examina-
tion and at 6-month intervals thereafter. Interrater reliabilities
for DBSs between the principal CUSPAD developer and a re-
search technician have been reported as follows: =0.88 when
concurrently rating a single interview and =0.67 when con-
ducting separate interviews.6
We used as predictors the following CUSPAD items (the pres-
ence of which during the last month before each interview was
scored dichotomously [ie, present or absent]): (1) wandering
(wandering away from home or from the caregiver), (2) ver-
bal outbursts, (3) physical threats/violence, (4) agitation/
restlessness, and (5) sundowning (increased confusion at night
or during evening compared with the day [often associated with
yelling, hyperkinesis, and anxiety]). Combining these items,
we created the following 2 additional variables: (1) the sum of
all the above symptoms (theoretical range, 0-5) and (2) the pres-
ence of any of the 5 symptoms (dichotomous).
At every 6-month visit, medications that the patients were
taking were recorded. All cholinesterase inhibitors and all neu-
roleptics were each grouped in a single category and consid-
ered as dichotomous variables in the analyses.
A modified version24,25 of the Charlson Index of Comorbid-
ity29 (hereinafter referred to as the Comorbidity Index) from
the initial evaluation was also calculated.
Outcomes
Cognitive Outcome. Neurologic and mental status examina-
tions were conducted at study entry and at 6-month intervals
thereafter. If patients were unable to come to the outpatient clinic
for evaluation, they were visited at their homes, nursing homes,
or health care facilities. The cognitive function measure used
for the analysis was the Columbia MMSE (a 57-point modifi-
cation and expansion of the original Folstein MMSE23-25,27,28).
We used a Columbia MMSE score of at least 20 of 57 (approxi-
mately equivalent to a Folstein MMSE score of 10 of 30) as
the cognitive end point. This cutoff was chosen because similar
scores have been used as outcomes by many other stud-
ies,2,30,31 including our own.24,25 Exploratory analyses of neigh-
boring end points did not change the results. Education-
related differential item functioning of different Columbia MMSE
components may result in biased selection of cutoffs.32 This prob-
ably is less of a problem in our study, which includes only a
few subjects with low levels of education. We also included edu-
cation as a covariate in our analyses.
Functional Outcome. Functional capacity was assessed using
parts I and II of the Blessed Dementia Rating Scale (BDRS),33
with a range 0 to 17 and higher scores indicating worse func-
tional status. We chose a BDRS score of at least 10 of 17 as the
functional end point. The rationale for the functional cutoff was
similar to the one described for the cognitive cutoff.24,25 Again,
exploratory analyses of neighboring BDRS end points gave simi-
lar results.
Institutionalization.The equivalent institutional care34 that the
patient was receiving was rated at each 6-month follow-up in-
terval. This rating is the second section of a dependency scale
that rates the patient’s need for care (intraclass correlation co-
efficient, 0.73).34 It summarizes the interviewer’s impression,
based on data from the entire study protocol, of the care the
patient receives or requires, regardless of the patient’s loca-
tion. We used the equivalent institutional care rating of health-
related facility as an end point for prediction.24,25 Administra-
tion of the CUSPAD and the assessment of equivalent
institutional care were performed by the same person. Al-
though the raters were not aware of the specific study hypoth-
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eses, this could still represent a source of potential bias. Be-
cause of this, we also used actual (rather than equivalent)
placement in a nursing home, a retirement home, or an as-
sisted living facility as an outcome in supplementary analyses.
Death.We typically learned of patients’ deaths from family mem-
bers or when we attempted to schedule follow-up visits. For pa-
tients who could not be contacted for follow-up or who were oth-
erwise lost to follow-up in the US centers, death information was
obtained as available through the National Death Index.
STATISTICAL ANALYSES
To describe the course of DBSs over time, we graphed the pres-
ence of these symptoms since disease onset (as estimated by
the clinicians at the first evaluation) and estimated annual
changes using generalized estimating equations. The DBS sum
was the dependent variable in this model. The model consid-
ered the effect of time for every evaluation (in years since the
initial evaluation). A significant time effect indicates a marked
change in disruptive behavioral sum scores over time.
We calculated separate Cox proportional hazards models with
the following dichotomous outcomes: cognitive end point, func-
tional end point, institutionalization, and death. Duration (in
6-month blocks) between the initial visit and either develop-
ment of the outcome or last evaluation without the outcome served
as the timing variable in each of these models. The main predic-
tors in the Cox models were the DBS sum (as a continuous time-
dependent covariate) and the presence of any DBS (as a dichoto-
mous time-dependent covariate). In additional Cox models, all
5 individual DBSs (time-dependent) were simultaneously in-
cluded in the analyses. Predictor values are considered from visit-
assessments, not including (6-month lag) the visit-assessment
when theoutcomeoccurs.Different imputationstrategies for evalu-
ations with missing data (ie, using the value of the previous avail-
able visit or using the mean value of the previous and the follow-
ing available visits) produced similar results.
Although initial Cox models were unadjusted, in subse-
quent ones we simultaneously controlled for the following vari-
ables: cohort (Predictors Study 1 or 2 cohort; dichotomous),
recruitment center (dummy variable, with the New York cen-
ter as the reference), age at intake in the study, sex, education
in years, Columbia MMSE score at initial evaluation, BDRS score
at initial evaluation, the Comorbidity Index (dichotomous), neu-
roleptic use (time dependent), and cholinesterase inhibitor use
(time dependent).
RESULTS
Overall, 497 patients with AD, approximately half from each
Predictors Study cohort, were included in the study
(Table 1). Most of the patients were recruited from the 3
centers in the United States, and patients were at rela-
tively early stages of AD. The mean±SD estimated dura-
tion of illness at the time of recruitment was 4.1±2.3 years.
The patients were, on average, well educated and in good
general health. Patients were followed up from 0.1 to 14.0
years, during which time there were 3438 visit-
assessments of DBSs (average, 6.9, or25 per patient). Dur-
ing the follow-up period for each patient, missed visits were
rare; fewer than 18% of patients missed more than 1 semi-
annual visit and fewer than 9% missed more than 2. Fol-
low-up was complete for 94% of the cohort, whereas only
6% of the cohort (n=27) had missing follow-up informa-
tion for the year before the most updated data entry.
Most of the patients developed DBSs at some point dur-
ing follow-up (cumulative prevalence, 83%). Through-
out the follow-up period, patients with AD manifested,
on average, more than 2 DBSs (mean±SD, 2.3±1.5). Agi-
tation/restlessness was the most common (manifested by
approximately 3 of every 4 patients), followed by verbal
outbursts and sundowning (manifested by approxi-
mately 1 of every 2 patients), whereas wandering and
physical threats/violence were the least common (still
noted in approximately 1 of every 3 patients). Overall,
the presence of DBSs tended to increase over time
(Figure); generalized estimating equation models indi-
cated that the DBS sum increased by 0.07 for every year
of follow-up (P .001).
The presence of DBSs was associated with increased
risk of cognitive decline, functional decline, and insti-
tutionalization in the unadjusted and adjusted models
(Table 2). The presence of these symptoms was asso-
ciated with an approximately 1.5 times higher risk of
reaching the stated outcomes. Overall, 179 patients (38%)
were actually placed in a nursing home, a retirement
home, or an assisted living facility. Use of actual place-
ment as the outcome produced similar results (unad-
justed DBS sum: HR, 1.31 [95% confidence interval (CI),
1.16-1.49; P .001]; adjusted DBS sum: HR, 1.23 [95%
Table 1. Demographic and Clinical Characteristics
of Patientsa
Characteristic Finding
Cohort 1/cohort 2 250 (50)/247 (50)
Recruitment center
New York, New York 187 (38)
Baltimore, Maryland 128 (26)
Boston, Massachusetts 113 (23)
Paris, France 38 (8)
Larissa, Greece 31 (6)
Duration of follow-up, mean±SD (range), y 4.4±3.1 (0.1-14.0)
Age at study entry, mean±SD (range), y 73.8±8.9 (46.0-99.0)
Education, mean±SD (range), y 13.1±4.0 (0-20)
Men 197 (40)
Comorbidity Index 0/ 1 331 (67)/166 (33)
Neuroleptic use at all evaluations 155 (31)
Cholinesterase inhibitor use at all evaluations 191 (41)
MMSE score at study entry, mean±SD
(range)
20.4±3.7 (5.0-30.0)
CMMSE score at study entry, mean±SD
(range)
38.3±7.4 (7.0-57.0)b
BDRS score at study entry, mean±SD (range) 3.6±2.2 (0.0-15.0)b
Equivalent institutionalization end point
at baseline
39 (8)b
Cognitive end point during follow-up 198 (40)
Functional end point during follow-up 207 (42)
Equivalent institutionalization during follow-up 253 (55)
Deceased during follow-up 242 (49)
Abbreviations: BDRS, Blessed Dementia Rating Scale; CMMSE, Columbia
Mini-Mental State Examination (MMSE).
aUnless otherwise indicated, data are expressed as number (percentage) of
patients.
bAt baseline, CMMSE values for 8 patients were below the cognitive end
point, BDRS values for 8 subjects were above the functional end point, and 39
patients had reached the institutionalization end point. If a subject had already
reached the end point at baseline, he or she did not contribute data to the
survival analyses of the same end point but was included in the survival
analyses of other end points and the mortality survival analyses.
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CI, 1.07-1.42; P=.004]). Sundowning predicted cogni-
tive decline, whereas wandering was the strongest pre-
dictor of functional decline and institutionalization. Agi-
tation/restlessness was significantly associated with
cognitive and functional decline (Table 2). Almost half
of the patients died during the follow-up period (Table 1).
Median survival from recruitment into the study was 6.6
(95% CI, 6.0-7.2) years. Disruptive behavior was not a
significant predictor of mortality in any of the models
(Table 2).
Neuroleptic use was associated with a higher risk of
reaching the functional (HR, 1.57 [95% CI, 1.06-2.34;
P=.02]) and institutionalization (HR, 1.57 [95% CI, 1.06-
2.33; P=.03]) end points, whereas there was no associa-
tion with the cognitive outcome or with mortality. Cho-
linesterase inhibitor use was associated with a lower risk
of institutionalization (HR, 0.47 [95% CI, 0.26-0.87;
P=.02]) and mortality (HR, 0.36 [95% CI, 0.15-0.85;
P=.02]), whereas there was no association with the cog-
nitive or the functional outcome.
Autopsy data were available for 96 patients. Of these,
93% had AD-type pathological changes (87% received the
pathological diagnosis of AD and 6% had senile changes
of the Alzheimer type). A pathological diagnosis of Lewy
body dementia was assigned to 21% of patients (coex-
isting with AD-type pathological changes in all but 1 pa-
tient). Calculating the survival models only within the
autopsied subsample and restricting the analyses to those
with AD-type pathological changes (ie, excluding sub-
jects with a pathological diagnosis of Lewy body demen-
tia) did not change the associations between disruptive
behavior and outcomes. When we compared patients with
and without a pathological diagnosis of Lewy body de-
mentia, there was no difference in the presence of any
DBS at baseline (2=1.15 [P=.28]), any DBS through-
out follow-up (2=0.53 [P=.47]), the DBS sum at base-
line (t=−0.10 [P=.92]), or the DBS sum at any visit
(t=−0.89 [P=.38]). Similarly, we detected no associa-
tion between the presence of individual DBSs and Lewy
body dementia diagnosis. Given the restricted sample size
of the autopsied subjects, our power to detect an asso-
ciation between any DBS at baseline and a pathological
diagnosis of AD vs Lewy body dementia was approxi-
mately 14%.
COMMENT
Disruptive behavioral symptoms were extremely com-
mon in this study; more than 80% of patients with AD
manifested them at some point during follow-up. More
importantly, DBSs predicted cognitive and functional de-
cline and were associated with a higher risk of institu-
tionalization, even after adjusting for multiple potential
confounders. Although our data should provide power
to detect mortality prediction effects similar in magni-
tude to the ones detected for the other outcomes (HR as
small as 1.45 according to calculations using baseline
DBS), we detected no association between disruptive be-
havior and mortality.
We found a notable discrepancy between the fre-
quency of DBSs between the first and all subsequent evalu-
ations: fewer than 60% of patients who had such symp-
toms at some point during the follow-up had them at the
first visit. These results likely relate to an increasing preva-
lence of these symptoms during the course of disease and
to the well-described fluctuation of these symptoms from
visit to visit.5,7 Therefore, our assessment of these symp-
toms at multiple visits rather than the usual approach of
considering them only at baseline could be a major ex-
planation for discrepancies in findings on the predictive
value of these symptoms.
We confirmed the associations between DBSs and the
risks of cognitive decline,1,10-15 functional decline,2,10,15 and
institutionalization16-19 noted by previous studies. Nev-
ertheless, our results are in discordance with some pre-
vious work that failed to detect significant associations
between disruptive behavior and cognition,2,16 func-
tion,15 or institutionalization.2 As in previous studies, agi-
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Figure. Disruptive behavioral symptoms (DBSs) during the course of
Alzheimer disease (for graphical purposes and because of the very few data
points beyond 20 years after disease onset, the follow-up has been truncated
to that point). A, Sum of all DBSs. B, Percentage of patients with any DBS.
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functional decline2,15-19 outcomes. In accordance with pre-
vious reports, wandering was a significant predictor of
functional decline but also the major predictor of insti-
tutionalization.10 The association between DBSs and the
above outcomes persisted despite controlling for medi-
cation effects. Survival in our study was similar to that
in a recent report that included patients with AD of simi-
lar severity at enrollment.35 Similar to some reports,2 but
unlike others,20 we detected no significant association be-
tween disruptive behavior and survival.
In the subsample of patients who underwent autopsy,
we detected no associations between DBSs and coexist-
ence (in addition to AD) of a pathological diagnosis of Lewy
body dementia. The underlying neurobiological process
of disruptive behavior is far from clear and has been at-
tributed to alterations in multiple neurotransmitter sys-
tems.36 Regarding the adrenergic system, it has been shown
that patients with AD who display aggressive behaviors
have a markedly higher level of 2, 1, and 2 adrenergic
receptors in the cerebellar cortex.37 There is also a rela-
tive preservation of inhibitory noradrenergic neuronal in-
put to the cerebellar cortex (tyrosine hydroxylase–
positive neuronal fibers) in patients with AD who exhibit
aggressive behavior.38 Regarding the serotoninergic sys-
tem, loss of serotonin2 (5-HT2) receptors in multiple cor-
tical areas39 and reduced density of 5-HT1A receptors in tem-
poral areas40 has been reported for patients with AD who
manifest aggressive behavior. Decreased 5-HT receptors
and 5-hydroxyindoleacetic acid levels in multiple corti-
cal areas for aggressive patients with AD were reported in
another study.41 Possible involvement of the serotonin sys-
tem in DBSs among patients with AD is also evidenced by
a series of pharmacotherapy studies.36,42 Regarding the do-
paminergic system, according to one report,43 patients with
AD and a history of unequivocal interpersonal violence
had significantly greater neuron counts in the substantia
nigra pars compacta than did nonviolent patients with AD.
According to another study,44 DBSs in patients with AD
were associated with polymorphisms in the dopamine re-
ceptor genes: aggression was significantly more frequent
in patients homozygous for the B2 genotype (B2/B2) of
theDRD1 gene. Successful treatment of aggression and agi-
tation with dopaminergic blockers provides additional sup-
port for involvement of the dopaminergic system in the
disruptive behavior of patients with AD.36,42 Overall, it is
also conceivable that the neurobiological changes relat-
ing to disruptive behavior may involve disturbed balance
in more than 1 neurotransmitter system.
This study has limitations. The patients with AD in
our study were selected from tertiary care university hos-
pitals and specialized diagnostic and treatment centers
and were well educated and extremely healthy. Also, the
proportion of nonwhite patients in our sample was very
small (5%). Thus, they constitute a nonrandom sample
of those affected by AD, and our results have limited ex-
ternal validity because they might not be generalizable
to population-based studies of patients with AD who are
of other ethnicities or other educational and comorbid-
ity strata. Although we used survival analyses, which take
advantage of variable follow-up times, a longer average
duration of follow-up with enrollment of patients at even
earlier stages of the disease might have provided more
complete conclusions. The DBSs were assessed as present
or absent. Although the severity of these symptoms is to
some extent accounted for in our models by consider-
ing medications used to treat disruptive behavior (ie, the
need to treat reflects symptoms’ severity according to clini-
cal judgment), we cannot fully investigate the effects of
frequency and intensity of DBSs. Medication use was
coded in a dichotomous fashion for broad categories of
Table 2. Cox Models Predicting Occurrence of the 4 Outcomes by DBSs as Time-Dependent Covariatesa
DBS
Outcome, HR (95% CI)
Cognitive Functional Institutionalization Death
Unadjusted models
Sum (0-5) 1.31 (1.18-1.45) 1.46 (1.32-1.61) 1.36 (1.24-1.49) 1.06 (0.97-1.16)
Any (0-1) 1.91 (1.40-2.62) 2.49 (1.78-3.48) 1.84 (1.40-2.41) 1.03 (0.79-1.34)
Wandering 2.09 (1.42-3.08) 1.96 (1.37-2.81) 1.99 (1.38-2.85)
Verbal outbursts
Physical threats/violence
Agitation/restlessness 1.65 (1.20-2.28) 1.78 (1.27-2.47)
Sundowning 1.57 (1.16-2.13) 1.45 (1.08-1.97) 1.49 (1.13-1.97)
Adjusted models
Sum (0-5) 1.21 (1.07-1.36) 1.31 (1.17-1.46) 1.23 (1.11-1.37) 1.03 (0.93-1.13)
Any (0-1) 1.45 (1.03-2.03) 1.66 (1.17-2.36) 1.47 (1.10-1.97) 0.94 (0.71-1.25)
Wandering 1.88 (1.27-2.78) 1.55 (1.05-2.29)
Verbal outbursts
Physical threats/violence
Agitation/restlessness 1.64 (1.16-2.33) 1.49 (1.06-2.11)
Sundowning 1.42 (1.03-1.97)
Abbreviations: CI, confidence interval; DBS, disruptive behavioral symptom; HR, hazard ratio.
aAdjusted models simultaneously controlled for cohort, recruitment center, age, sex, education, baseline Columbia Mini-Mental State Examination score,
baseline Blessed Dementia Rating Scale score, Comorbidity Index, use of cholinesterase inhibitors, and use of neuroleptics. In models considering the effect of the
DBS sum or any DBS, significant HRs are given in boldface. In models that simultaneously consider all individual DBSs, only the significant associations are
presented.
(REPRINTED) ARCH NEUROL / VOL 64 (NO. 12), DEC 2007 WWW.ARCHNEUROL.COM
1759
©2007 American Medical Association. All rights reserved.
Downloaded From: http://archneur.jamanetwork.com/ by a Columbia University User  on 01/28/2016
agents. Although we used a time-dependent approach for
the medication covariate, we cannot completely take into
account the potential effect of different pharmacologi-
cal substances, different doses, or alterations occurring
in intervals shorter than 6 months. Finally, the absence
of pathological correlates of DBSs may partially stem from
the qualitative pathological measures we have available
and from the limited power of the autopsy sample.
Confidence in our findings is strengthened by several
factors. This is, to our knowledge, one of the largest stud-
ies of its kind examining the issue of disruptive behavior
in AD, supplying enough power for detection and more pre-
cise calculation of effects of interest and ability to control
potential confounders. Inclusion of population from 2 Eu-
ropean centers improves the generalizability of the find-
ings. Clinical diagnosis and follow-up were performed by
physicians with specific expertise in dementia and were
based on the uniform application of widely accepted cri-
teria via consensus diagnostic conference procedures. The
clinical diagnosis of AD has been confirmed in a high pro-
portion of those who underwent postmortem evaluation
(93%).23,25 The patients were followed up prospectively,
which eliminates the potential biases inherent in deriving
information fromretrospectivemedical chart reviews.Evalu-
ations were performed semiannually, which provides mul-
tiple assessments of DBSs and therefore permits more ac-
curate coefficient calculations. They were also considered
in a time-dependent fashion. Our cohort had a very high
rate of follow-up participation with very few missing data.
Clinical signs of interest were ascertained and coded in a
standardized fashion at each visit. Most previous reports
studied more impaired patients with AD, capturing the part
of the disease course corresponding to more advanced
stages. Patients with AD were included from relatively early
stages so that the cohort captures most of the range of pro-
gression over time. Finally, we took medication adminis-
tration into account in a time-dependent manner, which
provides higher confidence that the occurrence of out-
comes of interest in the present study is strictly related to
the presence of DBSs rather than treatment for them.
Prognosis is a standard part of a medical evaluation,
and knowledge of prognostic indicators is important in-
formation to practitioners, patients, and families. These
data provide a basis for expanding our understanding of
disruptive behavior as a predictor in the course of AD.
The underlying pathophysiological substrate of the as-
sociations between such neuropsychiatric features and
clinical outcomes remains to be explored.
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